Introduction
Male sexual dysfunction refers to recurrent or persistent difficulty in maintaining satisfactory sexual activity. It may involve changes in sexual desire, erection, ejaculation, or orgasm. Ejaculatory disorders include premature ejaculation, retrograde ejaculation, and anejaculation. However, in clinical practice, the most frequent complaint is erectile dysfunction, defined as the persistent or recurrent inability to achieve and/or maintain an erection sufficient for satisfactory sexual activity.
This algorithm presents a structured approach to erectile dysfunction, integrating clinical assessment, laboratory investigation, cardiovascular risk stratification, and evidence-based therapeutic options.
Initial assessment
The approach should begin with a detailed medical history and a focused physical examination. It is particularly important to explore the sexual history, including libido, erection quality, the presence of nocturnal or morning erections, ejaculatory function, relationship factors, and the psychological impact of symptoms.
The physical examination should include cardiovascular, endocrine, and genital assessment. The presence of structural penile abnormalities, such as Peyronie disease, significant congenital curvature, or phimosis, is an indication for referral to secondary care.
Pelvic or perineal trauma
In the absence of evident anatomical abnormalities, a history of previous pelvic or perineal trauma should be investigated. Traumatic injuries may compromise penile blood supply or innervation and may justify specialist assessment by Urology.
Laboratory investigation
Laboratory assessment should include total testosterone, ideally measured while fasting and in the morning, between 8 and 10 a.m. Measurement of glycated haemoglobin and a lipid profile is also recommended because of the strong association between erectile dysfunction, diabetes mellitus, and cardiovascular disease.
When an endocrine disorder is suspected, TSH, FSH, LH, and prolactin may be requested. Signs warranting hormonal investigation include reduced libido, hypogonadism, loss of muscle mass, gynaecomastia, or suspected thyroid disease.
It is important to remember that the diagnosis of hypogonadism should not be based on a single testosterone value. Compatible symptoms and laboratory confirmation in two separate morning samples are required.
Medicines associated with erectile dysfunction
Several medicines may contribute to the development or worsening of erectile dysfunction. Among antihypertensive agents, non-selective beta-blockers, thiazide diuretics, spironolactone, methyldopa, and some calcium-channel blockers should be considered.
In psychiatric practice, antidepressants, including SSRIs, SNRIs, and tricyclic antidepressants, as well as antipsychotics, benzodiazepines, and lithium, should be considered. Other potentially implicated medicines include anticonvulsants, digoxin, gemfibrozil, 5-alpha-reductase inhibitors, antiandrogens, ketoconazole, methotrexate, and interferon alfa.
Whenever possible, substitution or optimisation of treatment should be considered.
Correction of risk factors and comorbidities
Before starting specific treatment, it is essential to correct potentially reversible factors. Obesity, physical inactivity, metabolic syndrome, diabetes mellitus, hypertension, dyslipidaemia, obstructive sleep apnoea, and smoking are strongly associated with erectile dysfunction.
Weight loss, regular physical exercise, and appropriate control of comorbidities may significantly improve erectile function while also reducing overall cardiovascular risk.
Cardiovascular risk stratification
Erectile dysfunction is frequently regarded as an early marker of cardiovascular disease. Therefore, cardiovascular risk stratification should be performed before pharmacological treatment is initiated.
Low-risk patients include asymptomatic individuals with fewer than three cardiovascular risk factors, previous uncomplicated myocardial infarction, or mild heart failure. Intermediate-risk patients include those with stable angina, recent myocardial infarction, or moderate heart failure. High-risk patients include those with unstable angina, severe heart failure, significant arrhythmias, or severe valvular disease.
Patients at intermediate or high risk may require additional cardiovascular assessment and possible specialist referral.
Treatment with phosphodiesterase type 5 inhibitors
After correction of reversible causes and appropriate cardiovascular assessment, phosphodiesterase type 5 inhibitors are the first-line pharmacological treatment.
The main options include sildenafil, tadalafil, vardenafil, and avanafil. The choice depends on the patient’s characteristics, the desired duration of action, the adverse-effect profile, and potential drug interactions.
Tadalafil has the longest duration of action and may remain effective for up to 36 hours. The absorption of sildenafil and vardenafil may be reduced by high-fat meals.
The most frequent adverse effects include headache, facial flushing, nasal congestion, and dyspepsia. Rare events, such as visual disturbances, priapism, or sudden hearing loss, should be explained to the patient.
Contraindications to PDE5 inhibitors
Concomitant nitrate use is an absolute contraindication because of the risk of severe hypotension. The safety interval between taking a PDE5 inhibitor and administering nitrates varies according to the molecule used and may be as long as 48 hours in the case of tadalafil.
Before prescribing, the patient’s regular medication and potential drug interactions should be carefully reviewed.
Treatment failure
When the response to PDE5 inhibitors is insufficient, it should be confirmed that the medicine has been used correctly. It is important to ensure an adequate dose, a sufficient number of attempts, appropriate sexual stimulation, and the correct interval between administration and sexual activity.
Many situations initially classified as treatment failure result from incorrect use of the medicine.
Suspected psychogenic aetiology
A psychogenic aetiology should be considered when symptoms have a sudden onset, the dysfunction is situational, erections are preserved during sleep or masturbation, performance anxiety is present, or there are significant relationship factors.
In these cases, referral to Psychiatry, Clinical Psychology, or Sexology may be useful as part of a multidisciplinary approach.
Referral
Referral to secondary care should be considered in the presence of Peyronie disease, relevant penile deformities, significant pelvic trauma, complex hypogonadism, contraindication to or failure of first-line treatments, or when advanced treatments such as intracavernosal injections or penile prosthesis are required.
Conclusion
Erectile dysfunction is a multifactorial condition requiring a comprehensive approach. Identification of reversible factors, appropriate hormonal assessment, cardiovascular risk stratification, and rational use of PDE5 inhibitors can improve sexual function while also helping to identify relevant systemic disease. The structured approach presented in this algorithm facilitates diagnosis, guides treatment, and helps identify patients who may benefit from specialist referral.